ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2020
FG-4592 Improves Depressive-Like Behaviors through HIF-1-Mediated Neurogenesis and Synapse Plasticity in Rats.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- A classic traditional chinese medicine formula for depression: mechanistic insights from phytochemical constituents and multitarget pathways.Psychopharmacology · 2026Pooled it
- Progress, critical challenges, and translational prospects of intranasal administration of botanical essential oils for the treatment of depression.Frontiers in pharmacology · 2025Pooled it
- A Systematic Review of Circulatory microRNAs in Major Depressive Disorder: Potential Biomarkers for Disease Prognosis.International journal of molecular sciences · 2022Pooled it
- HIF1 Stabilization by Roxadustat Improves Cognition and Prevents Neuron Loss in Alzheimer's Diseases In Vivo.Biology · 2026Article
- Hypoxia inducible factor-1α-driven signaling networks regulating adult neurogenesis via Notch, Wnt, and MAPK pathways.Molecular biology reports · 2026Review
- Electroacupuncture Ameliorates Depressive-Like Behaviors by Enhancing Autophagy to Attenuate Hippocampal Neuroinflammation via the VEGF/AKT1/ERK Pathway in CUMS Rats.Neurochemical research · 2026Article
- Computational biological analysis reveals that HIF-1 and FoxO signaling pathways influence cognitive impairment in patients with depression.Translational psychiatry · 2025Article
- Implications of neurogenesis in depression through BDNF: rodent models, regulatory pathways, gut microbiota, and potential therapy.Molecular psychiatry · 2025Review
- tsRNA, cell death and disease: Connecting the dots.Non-coding RNA research · 2025Review
- Prenatal psychological stress mediates vertical transmission of gut microbiome to the next generation affecting offspring depressive-like behaviors and neurotransmitter.BMC psychology · 2025Article
- Luteolin and its antidepressant properties: From mechanism of action to potential therapeutic application.Journal of pharmaceutical analysis · 2025Review
- Metabolomic Profiling Reveals Distinct Plasma Metabolic Signatures in Acne Patients with and without Depression.Clinical, cosmetic and investigational dermatology · 2025Article
- Antidepressant Properties of a Four-compound Cocktail Identified from Si-Ni-San by HIF-1 Pathway Modulation.Current computer-aided drug design · 2025Article
- Transcutaneous auricular vagus nerve stimulation regulates gut microbiota mediated peripheral inflammation and metabolic disorders to suppress depressive-like behaviors in CUMS rats.Frontiers in microbiology · 2025Article
- Identification and experimental validation of biomarkers associated with mitochondrial and programmed cell death in major depressive disorder.Frontiers in psychiatry · 2025Article
- Oligodendrocyte-derived exosomes-containing SIRT2 ameliorates depressive-like behaviors and restores hippocampal neurogenesis and synaptic plasticity via the AKT/GSK-3β pathway in depressed mice.CNS neuroscience & therapeutics · 2024Article
- Integrated bioinformatics and network pharmacology identifying the mechanisms and molecular targets of Guipi Decoction for treatment of comorbidity with depression and gastrointestinal disorders.Metabolic brain disease · 2024Review
- Pharmacological modulation of HIF-1 in the treatment of neuropsychiatric disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Chronic Kidney Disease Induces Cognitive Impairment in the Early Stage.Current medical science · 2023Article
- Nrf2 regulates iron-dependent hippocampal synapses and functional connectivity damage in depression.Journal of neuroinflammation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression, plus the accompanying memory impairment, is one of the leading causes of disability worldwide. Thus, there is a critical need to develop new drugs based on distinct strategies. FG-4592, an inhibitor of prolyl hydroxylase, activates the hypoxia-inducible factor-1 (HIF-1) pathway, to produce multiple effects on cell properties. Here, we examined whether FG-4592 has antidepressant effects, using a chronic unpredictable mild stress (CUMS) procedure to establish rodent depression models. We found that FG-4592 not only reversed depressive behaviors but also improved CUMS-induced memory impairment. Mechanistically, FG-4592 could play an important role in promoting hippocampal neurogenesis and synaptic plasticity. At the molecular level, FG-4592 was found to activate HIF-1 and cAMP-responsive element-binding protein/brain-derived neurotrophic factor signaling pathways in vivo, as well as promote the expression of postsynaptic density (PSD) proteins, PSD95 and Homer1. An examination of primary hippocampal neurons showed that FG-4592 promoted dendritic growth. Taken together, our results not only provide an experimental basis for the future application of FG-4592 in clinical treatment of depression but also support the argument that the HIF-1 signaling pathway is a promising target for the treatment of depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.